A recent study indicates that people who come off popular weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass far faster than those who end traditional lifestyle programs.
Research printed in a prominent medical journal demonstrates that while obese people frequently drop a large proportion of their total mass while using the jabs, the weight comes back at an average rate of nearly a kilo each month once they quit.
"Individuals buying these drugs must be cognizant of the danger of quick rebound weight gain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
Such speed of recovery means a return to original mass in about one and a half years.
Weighing Therapies
The research, which examined dozens of trials involving over 9,000 of participants, compared the results of GLP-1 agonists with conventional dieting.
The team note that people who lose weight through dieting usually experience a less rapid creep back—around 0.1 kg a month—once they finish.
Explaining the Fast Regain
Nutrition scientists believe the way of the injections explains the amplified weight return.
These medications copy a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Long-term administration of the hormone levels several times higher than normal could lead to the system to produce less of its endogenous hormone, and may also lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this medication leads to hunger is no longer kept in check, making binge eating much more probable."
A Chronic Condition?
The NHS advise the jabs for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
Many experts say that, given the high risk of weight regain, the therapy might need to be life-long.
This opinion is supported by pharmaceutical companies, who say that the findings "underscore the long-term character of obesity," similar to managing diseases like hypertension.
Patient Experiences
Users who have come off the jabs explain a powerful return of appetite.
"It felt as if a switch flipping and you're instantly starving," said a patient.
The struggle is worsened if individuals have not adopted permanent dietary or behavioural changes during therapy.
Growing Adoption
Survey data suggest that a significant number of adults in the UK have tried these injections in the past year, with interest being substantial.
- Use is more common among females compared to men.
- The 40s and 50s demographic shows the highest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are effective tools for weight loss, they are not a permanent fix and lasting health benefits likely depends on integrated behavioural management.
